SCYNEXIS (NASDAQ:SCYX) Stock Passes Below 200 Day Moving Average of $3.16

SCYNEXIS, Inc. (NASDAQ:SCYXGet Rating) shares crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $3.16 and traded as low as $2.54. SCYNEXIS shares last traded at $2.75, with a volume of 176,862 shares.

Analyst Upgrades and Downgrades

Separately, HC Wainwright cut their price target on shares of SCYNEXIS from $14.00 to $8.00 in a research note on Friday, May 13th.

SCYNEXIS Stock Up 8.7 %

The business’s 50 day moving average price is $2.04 and its 200-day moving average price is $3.16. The company has a debt-to-equity ratio of 1.14, a current ratio of 7.87 and a quick ratio of 7.78. The company has a market cap of $89.59 million, a P/E ratio of -1.82 and a beta of 2.06.

SCYNEXIS (NASDAQ:SCYXGet Rating) last issued its quarterly earnings results on Thursday, May 12th. The company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.23. The company had revenue of $0.69 million during the quarter, compared to analyst estimates of $0.70 million. During the same period in the prior year, the business earned ($0.23) EPS. On average, analysts anticipate that SCYNEXIS, Inc. will post -2.13 earnings per share for the current fiscal year.

Institutional Trading of SCYNEXIS

A number of institutional investors have recently bought and sold shares of SCYX. Citigroup Inc. acquired a new stake in SCYNEXIS during the 1st quarter worth $26,000. Chicago Partners Investment Group LLC boosted its position in shares of SCYNEXIS by 20.4% during the first quarter. Chicago Partners Investment Group LLC now owns 50,192 shares of the company’s stock worth $106,000 after purchasing an additional 8,517 shares in the last quarter. State Street Corp boosted its position in shares of SCYNEXIS by 9.3% during the first quarter. State Street Corp now owns 78,630 shares of the company’s stock worth $307,000 after purchasing an additional 6,694 shares in the last quarter. Wealth Effects LLC bought a new position in shares of SCYNEXIS during the fourth quarter worth $536,000. Finally, DAFNA Capital Management LLC bought a new position in shares of SCYNEXIS during the fourth quarter worth $740,000. Institutional investors and hedge funds own 55.69% of the company’s stock.

SCYNEXIS Company Profile

(Get Rating)

SCYNEXIS, Inc, a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC).

See Also

Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.